Literature DB >> 2148686

NMR investigation of mithramycin A binding to d(ATGCAT)2: a comparative study with chromomycin A3.

D L Banville1, M A Keniry, R H Shafer.   

Abstract

The binding of mithramycin A to the d(A1T2G3C4A5T6) duplex was investigated by 1H NMR and found to be similar to that of its analogue chromomycin A3. In the presence of Mg2+, mithramycin binds strongly to d(ATGCAT)2. On the basis of the two-dimensional NOESY spectrum, the complex formed possesses C2 symmetry at a stoichiometry of two drugs per duplex (2:1) and is in slow chemical exchange on the NMR time scale. NOESY experiments reveal contacts from the E-pyranose of mithramycin to the terminal and nonterminal adenine H2 proton of DNA and from the drug hydroxyl proton to both G3NH2 protons, C4H1' proton, and A5H1' proton. These data place the drug chromophore and E pyranose on the minor groove side of d(ATGCAT)2. NOE contacts from the A-, B-, C-, and D-pyranoses of mithramycin to several deoxyribose protons suggest that the A- and B-rings are oriented along the sugar-phosphate backbone of G3-C4, while the C- and D-rings are located along the sugar-phosphate backbone of A5-T6. These drug-DNA contacts are very similar to those found for chromomycin binding to d(ATGCAT)2. Unlike chromomycin, the NOESY spectrum of mithramycin at the molar ratio of one drug per duplex reveals several chemical exchange cross-peaks corresponding to the drug-free and drug-bound proton resonances. From the intensity of these cross-peaks and the corresponding diagonal peaks, the off-rate constant was estimated to be 0.4 s-1. These data suggest that the exchange rate of mithramycin binding to d(ATGCAT)2 is faster than that of chromomycin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2148686     DOI: 10.1021/bi00491a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Authors:  Patrick J Grohar; Girma M Woldemichael; Laurie B Griffin; Arnulfo Mendoza; Qing-Rong Chen; Choh Yeung; Duane G Currier; Sean Davis; Chand Khanna; Javed Khan; James B McMahon; Lee J Helman
Journal:  J Natl Cancer Inst       Date:  2011-06-08       Impact factor: 13.506

2.  Inhibitory effects of anthracyclines on partially purified 5'-3' DNA helicase of Plasmodium falciparum.

Authors:  Pongruj Rattaprasert; Pattra Suntornthiticharoen; Paviga Limudomporn; Kanthinich Thima; Porntip Chavalitshewinkoon-Petmitr
Journal:  Malar J       Date:  2022-07-11       Impact factor: 3.469

Review 3.  Prospects and challenges for the development of new therapies for Ewing sarcoma.

Authors:  Patrick J Grohar; Lee J Helman
Journal:  Pharmacol Ther       Date:  2012-10-18       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.